RETRACTED ARTICLE: Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer

Chen Xue1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Yuting He1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Qiuyue Hu1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Yan Yu1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Xiaolong Chen1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Jianan Chen1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Fang Ren2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Juan Li1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Zhigang Ren1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Guangying Cui1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]

Ranran Sun1 Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];2 Key Laboratory of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected];3 National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, [email protected]Correspondence[email protected]

show all

Abstract

Xue C, He Y, Hu Q, et al. Cancer Manag Res. 2018;10:5101–5112.

We, the Editors and Publisher of Cancer Management and Research, have retracted the published article. Concerns were raised about the integrity of the data in the article following the author’s request to correct images in Figures 2 and 3. It was found images from these figures had been duplicated within the article and with those from another article. Specifically,

The images for Figure 2D, GBC-SD, NC and PIM1-siRNA, have been duplicated with the images for Figure 3C, GBC-SD, NC and NOZ, PIM1-siRNA, respectively.
The images for Figure 2D, NOZ, NC, have been duplicated with the images from Figure 5d, Hep3B, PLK-4 from Bao J, Yu Y, Chen J, et al. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018;9:1045. https://doi.org/10.1038/s41419-018-1020-0.

When approached for an explanation, the authors were cooperative and provided some original data for their study, however, the provided data was not satisfactory, and the results could not be adequately verified. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors do not agree with this decision.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Keywords:

View retraction statement:

Downregulation of PIM1 Regulates Glycolysis and Suppresses Tumor Progression in Gallbladder Cancer [Retraction]

RETRACTED ARTICLE: Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer

Information for

Open access

Opportunities

Help and information

RETRACTED ARTICLE: Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer

Abstract

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature